| Q90081713 | Antibacterial Activity and Mode of Action of a Sulfonamide-Based Class of Oxaborole Leucyl-tRNA-Synthetase Inhibitors |
| Q27728279 | Benzoxaborole as a new chemotype for carbonic anhydrase inhibition |
| Q53682355 | Benzoxaborole treatment perturbs S-adenosyl-L-methionine metabolism in Trypanosoma brucei. |
| Q58842203 | Clinical and veterinary trypanocidal benzoxaboroles target CPSF3 |
| Q38191916 | From the Test Tube to the Treatment Room: Fundamentals of Boron-containing Compounds and their Relevance to Dermatology |
| Q35877494 | High-throughput screening against ~6.1 million structurally diverse, lead-like compounds to discover novel ROCK inhibitors for cerebral injury recovery |
| Q50099275 | Host-parasite co-metabolic activation of antitrypanosomal aminomethyl-benzoxaboroles |
| Q50940025 | In Silico Investigations of Chemical Constituents of Clerodendrum colebrookianum in the Anti-Hypertensive Drug Targets: ROCK, ACE, and PDE5. |
| Q103029076 | Ligand-induced conformational rearrangements regulate the switch between membrane-proximal and distal functions of Rho kinase 2 |
| Q37732551 | Nitroheterocyclic compounds are more efficacious than CYP51 inhibitors against Trypanosoma cruzi: implications for Chagas disease drug discovery and development |
| Q93011532 | Plasmodium falciparum Resistance to a Lead Benzoxaborole Due to Blocked Compound Activation and Altered Ubiquitination or Sumoylation |
| Q37672675 | Targeting Toxoplasma gondii CPSF3 as a new approach to control toxoplasmosis |
| Q58697517 | The trypanocidal benzoxaborole AN7973 inhibits trypanosome mRNA processing |
| Q48014676 | The versatility of boron in biological target engagement |
| Q90914855 | Unpacking the Pathogen Box-An Open Source Tool for Fighting Neglected Tropical Disease |